Nicollet Investment Management Inc. Sells 18,141 Shares of Novo Nordisk A/S $NVO

Nicollet Investment Management Inc. lessened its stake in Novo Nordisk A/S (NYSE:NVO) by 46.9% in the 4th quarter, Holdings Channel.com reports. The firm owned 20,572 shares of the company’s stock after selling 18,141 shares during the quarter. Nicollet Investment Management Inc.’s holdings in Novo Nordisk A/S were worth $1,047,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the company. Godfrey Financial Associates Inc. purchased a new position in Novo Nordisk A/S in the fourth quarter worth about $25,000. WealthCollab LLC grew its holdings in shares of Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after buying an additional 260 shares during the last quarter. American National Bank & Trust purchased a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $28,000. Maseco LLP bought a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $29,000. Finally, Jackson Grant Investment Advisers Inc. bought a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $29,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

NYSE NVO opened at $42.73 on Thursday. The company has a 50-day moving average price of $41.98 and a 200-day moving average price of $46.04. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $81.44. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $190.78 billion, a P/E ratio of 10.03, a PEG ratio of 3.78 and a beta of 0.78.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. The company had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. Equities research analysts anticipate that Novo Nordisk A/S will post 3.45 earnings per share for the current year.

Analyst Upgrades and Downgrades

NVO has been the topic of several analyst reports. Sanford C. Bernstein started coverage on Novo Nordisk A/S in a research report on Wednesday, March 18th. They issued an “outperform” rating and a $175.00 price objective on the stock. Jefferies Financial Group raised Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a report on Thursday, February 12th. Wall Street Zen upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, May 12th. Finally, Weiss Ratings cut Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, April 22nd. Four analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Novo Nordisk A/S has an average rating of “Hold” and a consensus price target of $65.56.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk reported that its Wegovy pill has surpassed 3 million prescriptions, signaling strong early demand for the oral obesity treatment and reinforcing the company’s competitive position versus Eli Lilly in the fast-growing GLP-1 market. Novo Wegovy Pill Tops 3M Prescriptions
• Positive Sentiment: The company also said that more than 80% of Wegovy pill customers have never used a GLP-1 before, which suggests the product is expanding Novo’s addressable market beyond existing obesity-drug users. Novo Nordisk CEO interview on Wegovy pill customers
• Positive Sentiment: Novo Nordisk introduced an updated Rybelsus tablet formulation in Canada, adding a more convenient version of its diabetes GLP-1 drug and supporting the company’s broader cardiometabolic franchise. Novo Nordisk introduces updated Rybelsus tablet formulation in Canada
• Neutral Sentiment: Several articles highlighted Novo Nordisk as a key beneficiary of the GLP-1 boom and as part of healthcare ETF exposure themes, which may keep the stock in focus but do not change fundamentals directly. Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
• Neutral Sentiment: Novo’s CEO reiterated that the company aims to be a “cardiometabolic powerhouse” with a diversified pipeline, reinforcing a long-term growth narrative. Novo Nordisk CEO interview
• Negative Sentiment: Novo Nordisk is also heading to court in South Africa to try to stop sales of unapproved semaglutide copies, underscoring ongoing legal and counterfeit-product risks tied to its blockbuster drugs. Novo Nordisk faces off in court with South African weight-loss drug compounder

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.